RT @HelenBranswell
In a surprisingly conflict-free #VRBPAC meeting, the committee voted 21-0 to support FDA's plan to move towards a simplified #Covid vaccination program with a single composition for primary series & boosters. https://www.statnews.com/2023/01/26/fda-advisers-recommend-updating-covid-vaccines/

so it appears that simplicity has replaced efficacy as the primary goal over at @US_FDA #VRBPAC #SARSCoV2 #CovidVaccines
---
RT @HelenBranswell
In a surprisingly conflict-free #VRBPAC meeting, the committee voted 21-0 to support FDA's plan to move towards a simplified #Covid vaccination program with a single composition for primary series & boosters. https://www.statnews.com/2023/01/26/fda-advisers-recommend-updating-covid-vaccines/
https://twitter.com/HelenBranswell/status/1618728193292406784

#Seroprevalence by #Vaccine and/or Natural Infection -gives an idea about current population level immunity

This will play a role in today's @US_FDA@twitter.com #VRBPAC meeting discussions

.@US_FDA@twitter.com #VRBPAC meeting 1/26/2023 meeting

Major objectives -Simplifying the process, future vaccine - composition/campaigns

Live link: https://www.youtube.com/watch?v=ZjULNuSYfd0

There's a #FDA #VRBPAC meeting on January 26th. These are meetings of outsideexperts to discuss safety and effectiveness of #vaccines and related biologics. Does anyone know what is on the agenda? Anything Covid related?
Dr Peter Hotez mentioned a need to evaluate boosters for the boosters; or updates to boosters...
Anywho... nothing on the FDA site yet.

https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-january-26-2023-meeting-announcement

Il panel della FDA raccomanda il vaccino Moderna a due dosi contro il COVID-19 per i bambini dai 6 ai 17 anni, nonostante i gravi problemi di sicurezza - eVenti Avversi #617anni #covid19 @istsupsan #eventiavversi #fda #moderna #News #vaccinicovid #VRBPAC #16giugno https://parliamodi.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